Friday, July 3 – Semaglutide may lower risk of serious complications in high-risk diabetes

On June 16, 2026, the US Food and Drug Administration (FDA) issued 25 warning letters to various telehealth companies alleging that their websites contained false or misleading claims about compounded semaglutide, tirzepatide, and, in one case, liraglutide products….By: McDermott Will & Schulte

Friday, July 3 – For decades, it’s been against the law for Medicare to pay for weight-loss medication. But that changed on July 1, with the launch of a new program called Bridge. It gives some people over 65, or who have Medicare for other reasons, access to some weight management medications if they meet certain weight and health criteria.

WEDNESDAY, July 1, 2026 — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) exposures reported to U.S. poison centers increased following 2021 U.S. Food and Drug Administration (FDA) approval for weight loss, according to a study published in the…

WEDNESDAY, July 1, 2026 — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) exposures reported to U.S. poison centers increased following 2021 U.S. Food and Drug Administration (FDA) approval for weight loss, according to a study published in…

Thursday, July 2 – Individuals with atrial fibrillation (Afib), or irregular heart rhythm, are at increased risk of stroke, chronic kidney disease and heart failure. These risks are significantly exacerbated if a type 2 diabetes diagnosis is added to the mix, says Md Mohaimenul Islam, Ph.D., research assistant professor in the Department of Pharmacy Practice in the University at Buffalo School of Pharmacy and Pharmaceutical Sciences.

Thursday, July 2 – (MedPage Today) — Patients with hidradenitis suppurative (HS) and a history of GLP-1 receptor agonist use for diabetes or obesity had significantly lower rates of multiple cardiovascular events and mortality, a large retrospective cohort study…

Thursday, July 2 – A form of fibre that boosts the release of the hunger-reducing hormone GLP-1 has been approved as safe by a European regulator, and could be added to foods within a year

Thursday, July 2 – Anthropic will begin developing drugs, BridgeBio pockets a billion, and more biotech news from The Readout

Thursday, July 2 – The federal government has launched a new program to make GLP-1 weight loss drugs more affordable for older Americans

Thursday, July 2 – Welcome to the “Temu experience of telehealth,” where everyone from Grindr to MAGA influencers can open a virtual clinic selling weight loss drugs and more.

Wednesday, July 1 – (MedPage Today) — Incretin-based therapies after bariatric surgery were associated with clinically meaningful augmented weight loss in a dose- and timing-dependent manner, according to U.S. cohort data. (eClinicalMedicine)
A Michigan couple was…

Wednesday, July 1 – Corxel Pharmaceuticals Ltd.’s oral small-molecule GLP-1 receptor agonist, CX-11, met the primary endpoints in a phase II trial evaluating the candidate in obese and overweight patients in the U.S., according to top-line results.

Wednesday, July 1 – A new pilot program will allow Medicare Part D beneficiaries to access popular weight loss drugs, including Wegovy, Zepbound and Foundayo, at a significantly reduced price for a limited time. NBC News medical contributor Dr. John Torres joins TODAY to break down the details.

Tuesday, June 30 – A growing body of evidence shows that GLP-1 drugs benefit cardiovascular health. Image Credit: Healthline/Munro/Getty Images

GLP-1 medications like Ozempic and Wegovy help protect heart health, but stopping the medications may reduce the protective effects.

Some research suggests that GLP-1s containing tirzepatide (Zepbound, Mounjaro) may help lower the risk of further complications in people with cardiovascular disease.

Other research suggests that GLP-1s may help reduce thromboembolic events, such as deep vein thrombosis (DVT), in people with obesity and autoimmune diseases.

Tuesday, June 30 – Scientists at The Wistar Institute have shown that a single injection of a small, circular piece of genetic instruction can produce weight loss and blood glucose control in murine models that lasts up to 10 times as long as incretin-mimicking drugs like Ozempic and Wegovy. If shown to be successful in clinical trials, this new method of delivery could eliminate the need for repeated dosing, which currently limits patient access and adherence to these therapies.

Tuesday, June 30 – (MedPage Today) — At the American Diabetes Association annual meeting, 2-year results from the SUPPRESS-EARLY trial showed that initiating tirzepatide (Mounjaro, Zepbound) early in the course of type 2 diabetes led to substantially higher rates…

Tuesday, June 30 – Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as Ozempic or Wegovy, have revolutionized type 2 diabetes and weight-loss management, but they have also led to some unfortunate outcomes. A recent study in JAMA Psychiatry has raised concerns that GLP-1 medications may be misused by people with eating disorders. These are serious mental health conditions in which thoughts about food, body weight and body shape become overwhelming, leading to harmful eating behaviors and an intense drive to control food intake. Although concerns about weight or appearance are common, eating disorders go far beyond these everyday worries.

Saturday, June 27 – GLP-1 drugs can provide benefits that may boost an athlete’s performance, but do these medications give them the competitive edge? Getty Images/The Good Brigade

Debates are emerging over whether GLP-1 drugs boost athletic performance.

However, experts say the loss of lean mass associated with using these drugs may cancel out any competitive advantages.

Saturday, June 27 – (MedPage Today) — Use of GLP-1 receptor agonists was associated with a higher risk of smell and taste disturbances among adults with type 2 diabetes, an analysis of electronic health record (EHR) data suggested.
Compared with matched controls…

Saturday, June 27 – “‘Mommy has to take shots to conform to what other people think will look better.'”View Entire Post ›

Saturday, June 27 – A report about unusual access to an experimental obesity drug has raised interest in the condition pulmonary hypertension.

Friday, June 26 – Some GLP-1 users report changes in their taste and smell, according to a new study. Tatsiana Volkava/Getty Images

Researchers report that GLP-1 drugs used to treat type 2 diabetes may impair a person’s sense of taste and smell.

Experts say taste and smell dysfunction doesn’t appear to be a common side effect of GLP-1s, which are widely prescribed for weight loss.

Friday, June 26 – As the use of GLP-1 medications for weight loss surges, so do calls to U.S. poison control centers, according to a new study.

Friday, June 26 – (MedPage Today) — In patients with inflammatory bowel disease (IBD), the use of GLP-1 receptor agonists was linked to a lower risk of colorectal cancer (CRC), according to a retrospective study presented at the American Society of Clinical Oncology…

Friday, June 26 – As people age, they often develop chronic conditions, many of which need to be managed with multiple prescription medications. While medications are important for disease management, polypharmacy poses an increased risk for harmful side effects and contraindications.

THURSDAY, June 25, 2026 — As the use of GLP-1 medications for weight loss surges, so do calls to U.S. poison control centers, according to a new study.
A team led by Jordan Miller of the University of Texas at San Antonio analyzed reports…

Friday, June 26 – A new strategy for delivering GLP-1 drugs to patients with obesity or who were overweight resulted in up to a 12% reduction in body weight after 36 weeks, according to a randomized phase II clinical trial published in Nature Medicine.

Thursday, June 25 – An estimated 14 million Medicare Part D recipients could obtain Wegovy, Foundayo, and Zepbound for $50 per month. Johner Images/Getty Images

Federal officials announced the launch of a Medicare GLP-1 Bridge pilot program that reduces the cost of certain GLP-1 medications prescribed for weight loss.

Under the program, Wegovy, Foundayo, and Zepbound KwikPens will cost $50 per month for eligible participants enrolled in Medicare Part D plans.

The program begins on July 1 and continues through Dec. 31, 2027.

Some Medicare recipients will soon be able to purchase a limited number of GLP-1 weight loss drugs at a guaranteed price of $50 per month.

Thursday, June 25 – People are getting more care and using lots of GLP-1 drugs, fueling a sharp increase in health care spending.

Drug buyers want a New York federal judge to preserve proposed class claims accusing Novo Nordisk of paying Teva to delay generic competition with its Victoza GLP-1 drug, arguing that whatever the underlying deal was, no generic version materialized when it could have.  

Thursday, June 25 – (MedPage Today) — Use and misuse of GLP-1 receptor agonists were common in people with eating disorders, interim results of an ongoing cross-sectional study suggested.
Among over 400 people with eating disorders, 32.1% said they have used GLP…

Eli Lilly and Co. posted $19.8 billion in first-quarter 2026 revenue, driven by tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity. The Indianapolis-based drugmaker is channeling cash flow from these blockbuster GLP-1 drugs into an aggressive dealmaking campaign — about $25.1 billion across 10 announced acquisitions so far this year and more than $26 billion in other closed deals.

Corxel Pharmaceuticals Ltd.’s oral small-molecule GLP-1 receptor agonist, CX-11, met the primary endpoints in a phase II trial evaluating the candidate in obese and overweight patients in the U.S., according to top-line results.

Wednesday, June 24 – Giving an individual special access to an experimental obesity drug is highly unusual.

Wednesday, June 24 – The “triple-G” weight loss drug, Pfizer’s lung cancer trial results, and more biotech news from The Readout

Wednesday, June 24 – Eli Lilly’s weight-loss franchise—including the tirzepatide products Mounjaro and Zepbound, and the weight-loss pill Foundayo—is projected to account for nearly half of the total sales of the top 10 drugs in 2032.

Tuesday, June 23 – Wegovy, Zepbound named first choice for obesity treatment in new guidelines

Tuesday, June 23 – Researchers say that GLP-1 drugs containing tirzepatide (Zepbound, Mounjaro) may lead to greater weight loss. Image Credit: Tatsiana Volkava/Getty Images

A meta-analysis found that one type of GLP-1 medication may be more effective than others. 

The analysis showed that GLP-1s containing tirzepatide (Zepbound, Mounjaro) helped people lose more weight than those containing semaglutide (Ozempic, Wegovy). 

Liraglutide (Saxenda) had the lowest weight loss percentage among users. 

The success of tirzepatide may be due to its dual mechanism, which targets multiple receptors.

Tuesday, June 23 – (MedPage Today) — At the American Diabetes Association annual meeting, updated phase II data from the VESPER program showed that patients who achieved weight loss with a weekly dose of the ultra-long-acting investigational GLP-1 agonist berobenatide…